Esketamine for Treatment-Resistant Depression in Pakistan: A Promising Strategy
Hospital Pharmacy October 23, 2025 Moomal Memon, Rukhsana Gul, Arif Gul et al. 1 citation
Depression, projected to be the leading cause of global disability by 2030, affects up to 19.62% of Pakistan's population. Treatment-resistant depression (TRD), characterized by poor response to at least two antidepressants, poses a major clinical challenge. Although interventions like ECT exist, their use is limited by systemic barriers. Esketamine, an NMDA receptor antagonist, offers a...